Approximately 30 million people worldwide suffer from FH. These patients have an increased risk of atherosclerotic CV disease and its atherothrombotic complications already in middle age. It is likely that COVID-19 further increases their cardiovascular risk, both during infection and after recovery. We advise continued use of treatment for the severe hypercholesterolaemia observed in these patients.
Please find the article HERE.